Epifanova M V, Chalyi M E, Gvasaliya B R, Eremin I I, Pulin A A, Nadelyaeva I I, Artemenko S A, Galitskaya D A, Repin A M
Research Institute for Uronephrology and Human Reproductive Health, Moscow, Russia.
Department of Urology, I.M. Sechenov First MSMU, Moscow, Russia.
Urologiia. 2017 Dec(6):138-143.
Prostate cancer (PCa) is one of the most common maligmancies and causes of death among men. Radical prostatectomy (RP) is optimal and recommended treatment modality for localized prostate cancer. More than half of all men undergoing surgery experience problems with erectile function and existing treatments do not provide a positive effect. Thus, there is a need for new approaches to the restoration of erectile function in patients after RP. One of these is the use of cell technologies, namely the stromal-vascular fraction and autologous platelet-rich plasma. This review examines the results of preclinical and clinical studies investigating the efficacy and safety of these treatment options in erectile dysfunction.
前列腺癌(PCa)是男性中最常见的恶性肿瘤和死亡原因之一。根治性前列腺切除术(RP)是局限性前列腺癌的最佳推荐治疗方式。超过一半接受手术的男性会出现勃起功能问题,且现有治疗方法效果不佳。因此,需要新的方法来恢复RP术后患者的勃起功能。其中一种方法是使用细胞技术,即基质血管成分和自体富血小板血浆。本综述考察了关于这些治疗方案在勃起功能障碍方面疗效和安全性的临床前及临床研究结果。